Literature DB >> 9849639

Identification of cytochrome P450 isozymes involved in metabolism of the alpha1-adrenoceptor blocker tamsulosin in human liver microsomes.

H Kamimura1, S Oishi, H Matsushima, T Watanabe, S Higuchi, M Hall, S G Wood, L F Chasseaud.   

Abstract

1. The in vitro human liver metabolism of the alpha1-adrenoceptor blocker tamsulosin was investigated. When 14C-tamsulosin was incubated with human liver microsomes, it was converted to five known urinary metabolites and at least three unknown metabolites. Of the former group, the predominant metabolite was the O-deethylated metabolite (M-1), followed by the o-ethoxyphenoxy acetic acid (AM-1) and the m-hydroxylated metabolite (M-3). 2. There was a good linear relationship between AM-1 formation and testosterone 6beta-hydroxylase activity in microsomes from each of 10 individual donors. The rate of M-1 formation also correlated with the same activity, albeit the correlation curve did not pass through the origin. By contrast, the rates of M-3 and the O-demethylated metabolite (M-4) formation correlated with dextromethorphan O-demethylase activity. 3. Ketoconazole strongly inhibited AM-1 formation and reduced that of M-1 by c. 60%. Immunoinhibition studies using anti-rat antibodies supported these results. The formation of M-3 and M-4 was inhibited by quinidine and sparteine. 4. It is concluded that formation of tamsulosin metabolites, AM-1 and M-1, is catalysed by CYP3A4 whereas that of M-3 and M-4 is catalysed by CYP2D6. However, minor contributions from other CYPs cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9849639     DOI: 10.1080/004982598238985

Source DB:  PubMed          Journal:  Xenobiotica        ISSN: 0049-8254            Impact factor:   1.908


  14 in total

1.  Population pharmacokinetics of tamsulosin hydrochloride in paediatric patients with neuropathic and non-neuropathic bladder.

Authors:  Yasuhiro Tsuda; Shinji Tatami; Norio Yamamura; Yusuke Tadayasu; Akiko Sarashina; Karl-Heinz Liesenfeld; Alexander Staab; Hans-Günter Schäfer; Ichiro Ieiri; Shun Higuchi
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

Review 2.  Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.

Authors:  Gabriela Franco-Salinas; Jean J M C H de la Rosette; Martin C Michel
Journal:  Clin Pharmacokinet       Date:  2010-03       Impact factor: 6.447

3.  Effects of strong CYP2D6 and 3A4 inhibitors, paroxetine and ketoconazole, on the pharmacokinetics and cardiovascular safety of tamsulosin.

Authors:  Joachim Troost; Shinji Tatami; Yasuhiro Tsuda; Michaela Mattheus; Ludwig Mehlburger; Martina Wein; Martin C Michel
Journal:  Br J Clin Pharmacol       Date:  2011-08       Impact factor: 4.335

4.  Effects of CYP2D6 and CYP3A5 genetic polymorphisms on steady-state pharmacokinetics and hemodynamic effects of tamsulosin in humans.

Authors:  Kyoung-Ah Kim; In-Bae Park; Ji-Young Park
Journal:  Eur J Clin Pharmacol       Date:  2018-06-13       Impact factor: 2.953

5.  Human hepatocytes and cytochrome P450-selective inhibitors predict variability in human drug exposure more accurately than human recombinant P450s.

Authors:  Bo Lindmark; Anna Lundahl; Kajsa P Kanebratt; Tommy B Andersson; Emre M Isin
Journal:  Br J Pharmacol       Date:  2018-04-19       Impact factor: 8.739

Review 6.  Tamsulosin: an update of its role in the management of lower urinary tract symptoms.

Authors:  Katherine A Lyseng-Williamson; Blair Jarvis; Antona J Wagstaff
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 7.  Dutasteride/tamsulosin: in benign prostatic hyperplasia.

Authors:  Gillian M Keating
Journal:  Drugs Aging       Date:  2012-05-01       Impact factor: 3.923

Review 8.  Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms.

Authors:  Christopher J Dunn; Anna Matheson; Diana M Faulds
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

9.  Differential effects of the enantiomers of tamsulosin and tolterodine on P-glycoprotein and cytochrome P450 3A4.

Authors:  Aneta Doricakova; Dirk Theile; Johanna Weiss; Radim Vrzal
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-09-27       Impact factor: 3.000

10.  Interaction between udenafil and tamsulosin in rats: non-competitive inhibition of tamsulosin metabolism by udenafil via hepatic CYP3A1/2.

Authors:  H E Kang; S K Bae; M Yoo; D C Lee; Y G Kim; M G Lee
Journal:  Br J Pharmacol       Date:  2009-02-26       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.